Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Cagrilintide represents a novel approach to obesity management
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Subscribe To Our Newsletter & Stay Updated
